An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

PHASE3RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 13, 2024

Primary Completion Date

June 2, 2027

Study Completion Date

June 30, 2027

Conditions
Hematologic MalignancySolid TumorAdvanced Malignancies
Interventions
DRUG

Pelabresib

Small molecule inhibitor of bromodomain and extraterminal (BET) protein

Trial Locations (15)

2020

RECRUITING

ZNA Cadix-Hematology, Antwerp

8000

RECRUITING

Az St-Jan Brugge-Oostende A.V., Bruges

10029

RECRUITING

Mount Sinai Hospital - Oncology, New York

10065

RECRUITING

Weill Cornell Medicine - New York Presbyterian Hospital (Oncology), New York

21100

RECRUITING

AO Ospedale di Circolo, PO Varese (Ematologia), Varese

28100

ENROLLING_BY_INVITATION

Azienda Ospedaliero - Universitaria Maggiore della Carità (SCDU Ematologia), Novara

50141

RECRUITING

AOU Careggi (Department of Experimental and Clinical Medicine), Florence

90095-8344

RECRUITING

Hematologic Malignancy/Stem (Department of Medicine, Division of Hematology/Oncology), Los Angeles

32224-1865

RECRUITING

Mayo Clinic (Cancer Clinical Research Office), Jacksonville

60611-5957

RECRUITING

Northwestern Memorial Hospital (Oncology), Chicago

48109-5000

RECRUITING

UMHS - University of Michigan Medical Center (Radiation Oncology), Ann Arbor

1081 HV

RECRUITING

Amsterdam UMC location Vumc (Hematology), Amsterdam

CF14 4XW

RECRUITING

Cardiff and Vale University Health Board - University Hospital Wales (Hematology), Cardiff

G12 0YN

RECRUITING

Beatson West of Scotland Cancer Centre (Hematology), Glasgow

SE1 9RT

RECRUITING

Guys and St Thomas' Hospital - Haematology, London

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY